Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Base editing of key residues in the BCL11A-XL-specific zinc finger domains derepresses fetal globin expression

24 Jan 2024

Abstract excerpt

BCL11A-XL directly binds and represses the fetal globin (HBG1/2) gene promoters, using 3 zinc-finger domains (ZnF4, ZnF5, and ZnF6), and is a potential target for β-hemoglobinopathy treatments. Disrupting BCL11A-XL results in derepression of fetal globin and high HbF, but also affects hematopoietic stem and progenitor cell (HSPC) engraftment and erythroid maturation. Intriguingly, neurodevelopmental patients with...

Topics

Join the communities discussing this publication.

Genetics and Neurodevelopmental Disorders
Hemoglobinopathies and Related Disorders
Pancreatic function and diabetes

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38273654
DOI: 10.1016/j.ymthe.2024.01.023

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Base editing of key residues in the BCL11A-XL-specific zinc finger domains derepresses fetal globin expressionPMID 38273654Read ↗

Prioritization of The Zinc finger domain within <i>BCL11A by the</i> Amelioration capability of hemoglobinopathies using CRISPR-Cas9 technologySemantic proximity Read ↗

ZNF410 represses fetal globin by devoted control of CHD4/NuRDSemantic proximity Read ↗

Regulation of the fetal hemoglobin silencing factor BCL11ASemantic proximity Read ↗

Pathogenic BCL11A variants provide insights into the mechanisms of human fetal hemoglobin silencing.Semantic proximity Read ↗

Structural basis for human ZBTB7A action at the fetal globin promoterSemantic proximity Read ↗

C2H2 Zinc Finger Transcription Factors Associated with HemoglobinopathiesSemantic proximity Read ↗

Clinical-Scale Genome Editing of the Human BCL11A Erythroid Enhancer for Treatment of the HemoglobinopathiesSemantic proximity Read ↗

ZNF410 uniquely activates the NuRD component CHD4 to silence fetal hemoglobin expressionSemantic proximity Read ↗

Structural Insights into the DNA-Binding Mechanism of BCL11A: The Integral Role of ZnF6Semantic proximity Read ↗

Disruption of the BCL11A Erythroid Enhancer Reactivates Fetal Hemoglobin in Erythroid Cells of Patients with β-Thalassemia MajorSemantic proximity Read ↗

Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expressionSemantic proximity Read ↗

Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11ASemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.